Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

167 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non-Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR.
Watanabe M, Kawaguchi T, Isa S, Ando M, Tamiya A, Kubo A, Saka H, Takeo S, Adachi H, Tagawa T, Kakegawa S, Yamashita M, Kataoka K, Ichinose Y, Takeuchi Y, Sakamoto K, Matsumura A, Koh Y. Watanabe M, et al. Among authors: isa s. Clin Cancer Res. 2015 Aug 1;21(15):3552-60. doi: 10.1158/1078-0432.CCR-14-2151. Epub 2015 Apr 16. Clin Cancer Res. 2015. PMID: 25882755
Malignant pleural effusion from lung adenocarcinoma treated by gefitinib.
Kubo A, Koh Y, Kawaguchi T, Isa S, Okamoto I, Fukuoka J, Kusunoki Y, Kitaichi M, Takada M, Nakagawa K. Kubo A, et al. Among authors: isa s. Intern Med. 2011;50(7):745-8. doi: 10.2169/internalmedicine.50.4652. Epub 2011 Apr 1. Intern Med. 2011. PMID: 21467709 Free article.
Ethnic difference in hematological toxicity in patients with non-small cell lung cancer treated with chemotherapy: a pooled analysis on Asian versus non-Asian in phase II and III clinical trials.
Hasegawa Y, Kawaguchi T, Kubo A, Ando M, Shiraishi J, Isa S, Tsuji T, Tsujino K, Ou SH, Nakagawa K, Takada M. Hasegawa Y, et al. Among authors: isa s. J Thorac Oncol. 2011 Nov;6(11):1881-8. doi: 10.1097/JTO.0b013e31822722b6. J Thorac Oncol. 2011. PMID: 21841503 Free article.
Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA).
Kawaguchi T, Ando M, Asami K, Okano Y, Fukuda M, Nakagawa H, Ibata H, Kozuki T, Endo T, Tamura A, Kamimura M, Sakamoto K, Yoshimi M, Soejima Y, Tomizawa Y, Isa S, Takada M, Saka H, Kubo A. Kawaguchi T, et al. Among authors: isa s. J Clin Oncol. 2014 Jun 20;32(18):1902-8. doi: 10.1200/JCO.2013.52.4694. Epub 2014 May 19. J Clin Oncol. 2014. PMID: 24841974 Clinical Trial.
167 results